These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27324431)

  • 21. Severity dependent distribution of impairments in PSP and CBS: Interactive visualizations.
    Brittain C; McCarthy A; Irizarry MC; McDermott D; Biglan K; Höglinger GU; Lorenzl S; Del Ser T; Boxer AL; ; ; ;
    Parkinsonism Relat Disord; 2019 Mar; 60():138-145. PubMed ID: 30201421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PROSPERA: a randomized, controlled trial evaluating rasagiline in progressive supranuclear palsy.
    Nuebling G; Hensler M; Paul S; Zwergal A; Crispin A; Lorenzl S
    J Neurol; 2016 Aug; 263(8):1565-74. PubMed ID: 27230855
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Unexpected gender differences in progressive supranuclear palsy reveal efficacy for davunetide in women.
    Gozes I; Shapira G; Lobyntseva A; Shomron N
    Transl Psychiatry; 2023 Oct; 13(1):319. PubMed ID: 37845254
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imaging measures predict progression in progressive supranuclear palsy.
    Whitwell JL; Xu J; Mandrekar J; Gunter JL; Jack CR; Josephs KA
    Mov Disord; 2012 Dec; 27(14):1801-4. PubMed ID: 22415715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cognitive impairment in patients with multiple system atrophy and progressive supranuclear palsy.
    Brown RG; Lacomblez L; Landwehrmeyer BG; Bak T; Uttner I; Dubois B; Agid Y; Ludolph A; Bensimon G; Payan C; Leigh NP;
    Brain; 2010 Aug; 133(Pt 8):2382-93. PubMed ID: 20576697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-inflammatory drug use and progressive supranuclear palsy.
    Marras C; Cunningham CR; Hou J; Proudfoot J; Standaert DG; Juncos J; Riley D; Reich SG; Hall D; Kluger B; Bordelon Y; Shprecher DR; Litvan I;
    Parkinsonism Relat Disord; 2018 Mar; 48():89-92. PubMed ID: 29307562
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of survival in a series of clinically diagnosed progressive supranuclear palsy patients.
    dell'Aquila C; Zoccolella S; Cardinali V; de Mari M; Iliceto G; Tartaglione B; Lamberti P; Logroscino G
    Parkinsonism Relat Disord; 2013 Nov; 19(11):980-5. PubMed ID: 23968651
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Striatal dopaminergic lesions contributed to the disease severity in progressive supranuclear palsy.
    Chen MJ; Lu JY; Li XY; Jiao FY; Zuo CT; Wang J; Liu FT; Yang YJ
    Front Aging Neurosci; 2022; 14():998255. PubMed ID: 36092815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinimetric Analysis of the Motor Section of the Progressive Supranuclear Palsy Rating Scale: Reliability and Factor Analysis.
    Hall DA; Stebbins GT; Litvan I; Bordelon Y; Riley DE; Leverenz J; Standaert DG
    Mov Disord Clin Pract; 2016; 3(1):65-67. PubMed ID: 30363575
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minimally clinically important decline in the parkinsonian variant of multiple system atrophy.
    Krismer F; Seppi K; Wenning GK; Abler V; Papapetropoulos S; Poewe W
    Mov Disord; 2016 Oct; 31(10):1577-1581. PubMed ID: 27474888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A longitudinal study of motor, oculomotor and cognitive function in progressive supranuclear palsy.
    Ghosh BC; Carpenter RH; Rowe JB
    PLoS One; 2013; 8(9):e74486. PubMed ID: 24058574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pramipexole in progressive supranuclear palsy.
    Weiner WJ; Minagar A; Shulman LM
    Neurology; 1999 Mar; 52(4):873-4. PubMed ID: 10078747
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of faecal microbiota transplantation in patients with progressive supranuclear palsy-Richardson's syndrome: a phase 2, single centre, randomised clinical trial.
    Tian H; Wang J; Feng R; Zhang R; Liu H; Qin C; Meng L; Chen Y; Fu Y; Liang D; Yuan X; Zhai Y; Zhu Q; Jin L; Teng J; Ding X; Wang X
    EClinicalMedicine; 2023 Apr; 58():101888. PubMed ID: 36969340
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Review of Treatment Options for Progressive Supranuclear Palsy.
    Stamelou M; Höglinger G
    CNS Drugs; 2016 Jul; 30(7):629-36. PubMed ID: 27222018
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding fatigue in progressive supranuclear palsy.
    Ahn JH; Song J; Lee DY; Youn J; Cho JW
    Sci Rep; 2021 Aug; 11(1):16926. PubMed ID: 34413435
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bilateral pedunculopontine nucleus stimulation for progressive supranuclear palsy.
    Doshi PK; Desai JD; Karkera B; Wadia PM
    Stereotact Funct Neurosurg; 2015; 93(1):59-65. PubMed ID: 25662728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive Supranuclear Palsy and Statin Use.
    Bayram E; Marras C; Standaert DG; Kluger BM; Bordelon YM; Shprecher DR; Litvan I;
    Mov Disord; 2020 Jul; 35(7):1253-1257. PubMed ID: 32220093
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Associations Between Amantadine Usage, Gait, and Cognition in PSP: A
    Dale ML; Brumbach BH; Boxer AL; Hiller AL
    Front Neurol; 2020; 11():606925. PubMed ID: 33408688
    [No Abstract]   [Full Text] [Related]  

  • 39. The Non-Motor Symptom Profile of Progressive Supranuclear Palsy.
    Chaithra SP; Prasad S; Holla VV; Stezin A; Kamble N; Yadav R; Pal PK
    J Mov Disord; 2020 May; 13(2):118-126. PubMed ID: 32241079
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does corticobasal degeneration exist? A clinicopathological re-evaluation.
    Ling H; O'Sullivan SS; Holton JL; Revesz T; Massey LA; Williams DR; Paviour DC; Lees AJ
    Brain; 2010 Jul; 133(Pt 7):2045-57. PubMed ID: 20584946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.